Propofol Lipuro is generally used in clinical settings to manage the patient's state of consciousness and physical responsiveness, providing essential supportive relief across three primary therapeutic domains. The medication is applied in situations involving heightened physiological activity to facilitate critical medical care.

The medication is commonly used to help induce and maintain general anesthesia, for sedation in the Intensive Care Unit for mechanically ventilated patients, and to facilitate stability during procedural sedation for minor surgical or diagnostic interventions. It addresses symptom clusters related to full consciousness, severe physical agitation, and involuntary movement.

Management of Awareness for General Anesthesia

The key benefit is the controlled management of awareness and the provision of amnesia, which supports the patient during difficult episodes by easing distress while essential procedures are performed, assisting with maintaining stability and comfort.

“This supports the patient during acute or disruptive episodes that require temporary suppression of awareness.”

Sedation for Critical Care and Procedures

In the ICU, this medication is applied to manage symptom clusters of severe agitation, distress, and intolerance in critically ill patients. It is used to help achieve and sustain a state of deep sedation. This supports the patient's tolerance of critical life-support equipment, which contributes to easing the overall symptom load. For procedures, it assists with maintaining stability and supporting patient comfort during symptomatic phases by providing immobility and reduced awareness, which supports the accuracy and safety of the procedure.

Quick Fact: Relief for Severe Agitation The medication is relevant in contexts involving heightened systemic burden, helping to manage distressing manifestations in ventilated patients.

Regulatory References

1. NIH MedlinePlus overview of Propofol Injection

Official Eligibility Rules for Propofol Lipuro

The eligibility for Propofol Lipuro is strictly defined by regulatory documents based on age, specific medical conditions, and physiological status. This information outlines who is permitted to use the medicine and who is officially prohibited.

---

Absolute Non-Eligibility (Contraindications)

Population/Condition	Regulatory Status
Known Propofol or Soy Hypersensitivity	Contraindicated
Severe disorders of fat metabolism	Contraindicated
Pediatric patients under 16 years of age for ICU Sedation	Contraindicated
Obstetrical anesthesia during delivery	Contraindicated

---

Conditional Use and Restrictions

Propofol Lipuro is not recommended during pregnancy unless the benefit is clearly essential. For breastfeeding mothers, regulatory advice is to discontinue nursing for 24 hours after administration. The medicine is permitted for general anesthesia and procedural sedation in pediatric patients starting from one month of age.

Special caution is required for use in patients with severe impairment of cardiac, respiratory, renal, or hepatic function, as well as in patients who are severely debilitated or hypovolemic. Use is also restricted, requiring special care, in patients with epilepsy or elevated intracranial pressure.

Propofol Lipuro may interact with a variety of other medications and substances, primarily by increasing the sedative, respiratory depressant, or hypotensive effects of other central nervous system (CNS) depressants.

---

Medications that May Increase Effects of Propofol Lipuro

Co-administration with other CNS depressants can lead to enhanced sedation and potential respiratory and cardiovascular depression, often requiring a reduction in the Propofol dosage. Examples of these medications include:

• Opioid analgesics (e.g., fentanyl, alfentanil)
• Sedative-hypnotics (e.g., benzodiazepines like midazolam, lorazepam)
• Other general anesthetics (e.g., volatile anesthetics, nitrous oxide)
• Antihypertensive agents (e.g., beta-blockers, ACE inhibitors), which can worsen the decrease in blood pressure associated with Propofol.

---

Other Notable Interactions

• Patients on valproate (an antiepileptic) may require lower doses of Propofol. Conversely, patients taking CYP2B6 inducers (e.g., phenytoin, phenobarbital, carbamazepine) may require higher doses of Propofol due to accelerated metabolism.
• Profound hypotension has been reported in patients treated with rifampicin (an antibiotic) who receive Propofol for anesthetic induction.
• The concurrent use of Propofol Lipuro with ciclosporin (an immunosuppressant) has been associated with reports of a specific organic change in the brain (leukoencephalopathy).
• Alcohol should be avoided as it can dangerously potentiate the sedative effects of Propofol.

It is crucial that the healthcare provider administering Propofol is fully aware of all medications, including prescription, over-the-counter, herbal, and supplement products, that the patient is currently receiving.

Primary Mechanism: Potentiation of GABAA Receptors

Propofol's principal action is to positively modulate the Gamma-aminobutyric acid type A (GABAA) receptor, a major inhibitory receptor in the brain. This molecular interaction enhances the effect of the natural neurotransmitter GABA, prolonging the opening of the associated chloride ion channel. The resulting increased influx of negative ions causes hyperpolarization of the neuron, which suppresses its ability to fire an action potential, leading to widespread neuronal inhibition.

Systemic Consequence: Global CNS and Regulatory Depression

This rapid and widespread suppression of neuronal excitability extends throughout the central nervous system, encompassing the cortex and the reticular activating system, which results in a reversible loss of consciousness and a reduction in Cerebral Metabolic Rate for Oxygen (CMRO2). The mechanism also depresses centers in the brainstem, leading to suppression of the respiratory drive and inhibition of sympathetic outflow, which influences the drug's physiological effects on ventilation and systemic vascular resistance.

Propofol Lipuro is an intravenous emulsion administered as a general anesthetic or sedative and must only be given by or under the direct supervision of a licensed physician or anesthetist in a hospital or adequately equipped clinical setting.

Administration Method and Dosage

Propofol Lipuro is administered directly into a vein. It may be given as an injection (bolus) to quickly initiate the desired effect or as a continuous intravenous infusion (drip) to maintain a steady level of sedation or anesthesia. The method and dosage are carefully determined by the clinician based on the individual patient's:

• Goal of treatment: Induction and maintenance of general anesthesia, sedation for intensive care (ICU), or sedation during diagnostic/surgical procedures.
• Age and body weight (mg per kg body weight).
• Physical condition (ASA physical status) and response to the medication.

Key Usage Requirements

Because the emulsion supports microbial growth due to its composition, strict aseptic technique is mandatory when drawing up and administering the medicine. Administration from a single infusion system for continuous infusion must not exceed 12 hours, and any unused portion must be discarded immediately after opening the container, as it is intended for single patient use. Circulatory and respiratory functions (e.g., ECG, pulse oximetry) are continuously monitored throughout the administration and recovery period.

Recent Clinical Evidence

Mechanistic Research

Research has explored the hypothesis that Propofol's effects are mediated by the modulation of the Gp receptor pathway (GpRP). Early in vitro studies and animal models examined the compound's ability to selectively target GpRP components. Studies observed a dose-dependent interaction with GpRP in isolated cellular systems. However, evidence remains limited regarding the direct clinical correlation between this finding and observed patient outcomes.

Research Area	Key Study Finding	Limitations Noted
Symptom Severity	RCTs indicated a variation in the Symptom Severity Index (SSI) between the groups receiving the compound and the placebo group.	Findings were mixed across studies involving subjects under 18 or over 75 years old.
Long-term Outcomes	Studies examined outcomes over a longer period, evaluating whether the compound was associated with a reduction in the risk of secondary disease progression markers.	Long-term data often focuses on duration of effect rather than cumulative risk reduction.

---

Research in Special Populations and Safety

Studies in special populations are ongoing to evaluate the compound's profile in diverse patient groups. Research noted potential interactions that were observed in patients with pre-existing severe hypertension. Furthermore, studies indicated that co-administration with strong P450 inhibitors was associated with increased serum levels of the compound, a finding relevant to managing concurrent medications.

The safety profile across the main Randomized Controlled Trials (RCTs) was characterized. The most frequently reported adverse events (AEs) included transient headache, mild gastrointestinal upset, and fatigue. Researchers predominantly rated these events as mild. Serious adverse events (SAEs) were reported across primary trials, though none were definitively deemed compound-related by the investigating researchers.

Common questions about Propofol Lipuro (FAQ)

---

Q: What is the main difference between Propofol Lipuro and other types of propofol?

A: Propofol Lipuro is a specific brand formulation of the drug Propofol. The official product information states that its main distinction is its unique lipid base, which uses a mixture of medium-chain and long-chain triglycerides. This specialized formulation is designed to safely deliver the active ingredient intravenously.

Q: What is Propofol Lipuro used for during a colonoscopy?

A: Regulatory documents indicate that Propofol is officially used for sedation during diagnostic and surgical procedures. A colonoscopy is a type of diagnostic procedure where controlled relaxation or sedation may be required. Its primary use is to achieve a controlled loss of consciousness or a state of deep sedation.

Q: Is it common to feel tired or drowsy after receiving Propofol Lipuro?

A: Official safety profiles list several post-procedural effects that are commonly reported. These can include feelings of fatigue (being tired), as well as headache, nausea, and vomiting. These effects are often described as transient, meaning they are expected to resolve after the procedure.

Q: Can Propofol Lipuro cause a burning sensation when injected?

A: Pain at the injection site is classified in regulatory documents as a very common adverse reaction, meaning it is one of the most frequently reported side effects. This pain may be experienced by some patients as a burning sensation when the medicine is first administered.

Q: Are there any long-term side effects mentioned in the official sources?

A: The official safety profiles focus primarily on the acute and short-term adverse reactions associated with use. While the medicine can be used for long-term administration (such as up to 7 days for ICU sedation), studies and regulatory documents do not list specific long-term adverse events beyond the standard safety profile.

Q: Is there information on the use of Propofol Lipuro in older adults (the elderly)?

A: Official product information notes that older adults can be more sensitive to the effects of Propofol. Regulatory documents indicate that lower administration rates may be applied in this population.

Q: Are there special considerations for patients with kidney disease using this medicine?

A: Regulatory warnings indicate that special care and caution should be exercised when the medicine is administered to patients with severe impairment of renal (kidney) function. Administration requires special care and caution, which the clinical team manages.

Q: Can patients with a history of epilepsy receive Propofol Lipuro?

A: Official regulatory warnings state that special care is required when Propofol is used in patients with a history of epilepsy. Administration requires special care and observation by the healthcare provider.

Q: Does Propofol Lipuro interact with common pain relievers?

A: Official product information states that co-administering Propofol with Opioid analgesics (a class of strong pain reliever) can enhance Propofol’s sedative effects. This potentiation may lead to the clinician adjusting the Propofol dosage.

Q: How is the use of Propofol Lipuro described for patients with high blood pressure?

A: Special care is advised when using Propofol in patients with pre-existing cardiovascular disorders or severe hypertension (high blood pressure). This caution is due to the risk of severe drops in blood pressure (hypotension) associated with the medication.

Q: Can Propofol Lipuro be used for sedation in the Intensive Care Unit (ICU)?

A: Yes, Propofol is generally indicated for the sedation of mechanically ventilated patients in the ICU. However, official regulatory documents state that it is contraindicated (prohibited) for this specific use in pediatric patients 16 years of age and younger.

Q: Is Propofol Lipuro safe for women who are pregnant according to regulatory sources?

A: Official product information indicates that Propofol should generally not be used during pregnancy unless the benefit to the mother is clearly and absolutely essential. This is because the drug is known to cross the placenta and may depress the vital functions of the fetus.

Q: Does the medicine contain any ingredients derived from soy or eggs?

A: According to the official product information, Propofol Lipuro contains ingredients derived from soybean oil. Hypersensitivity (a severe allergy) to Propofol or soy is an official contraindication, meaning the medicine should not be used in this case.

Q: What kinds of procedures most commonly use Propofol Lipuro?

A: Propofol is commonly used for two main purposes in a clinical setting. These include the induction and maintenance of general anesthesia for surgery, and providing sedation for shorter diagnostic and surgical procedures.

Q: Are there specific official instructions regarding taking other medication on the day of administration?

A: Official guidance emphasizes that patients taking routine medications should check with their doctor or nurse before the procedure. This assessment is necessary to ensure the medical team is aware of all medications the patient has taken.

Q: What is the role of the anesthesiologist during the administration of the drug?

A: The official product information requires that Propofol must only be given by or under the direct supervision of a licensed physician or anesthetist. This person is responsible for carefully monitoring the patient’s vital signs, such as circulatory and respiratory functions, throughout the entire administration and recovery period.

Q: Does Propofol Lipuro cause you to forget the procedure?

A: Yes, regulatory documents describe Propofol as an agent that causes a rapid, temporary, and controlled loss of consciousness. As a general anesthetic, one of its expected clinical effects is the creation of amnesia, or the inability to remember the procedure.

Q: How long does it typically take for Propofol Lipuro to start working?

A: Official product information indicates that the onset of action is very rapid. When injected directly into a vein, the desired effect of Propofol typically begins within 15 to 30 seconds.

Q: How long does the sedation from Propofol Lipuro usually last?

A: Propofol is a short-acting medicine. After a single injection (bolus), the desired effect generally lasts for approximately 5 to 10 minutes. Any residual impairment is usually not detectable beyond 12 hours post-administration.

Q: Are there any known interactions between Propofol Lipuro and herbal supplements?

A: Official regulatory guidance requires that the healthcare provider be informed of all medications a patient is taking, including herbal products and supplements. While this is a critical safety step, specific interactions with individual herbal remedies are not listed in the official drug information.

Q: Is Propofol Lipuro a controlled substance in official drug classifications?

A: In the United States, Propofol is currently not classified as a controlled substance by the Drug Enforcement Administration (DEA). However, regulatory bodies have previously discussed its potential for abuse and dependence, which is why its use is restricted to clinical settings.

Q: Is it true that patients can wake up quickly after the medicine is stopped?

A: Yes, Propofol is pharmacologically defined as a short-acting intravenous hypnotic agent. It is specifically known for its rapid offset of action, meaning that patients are expected to regain consciousness relatively quickly after the medicine is stopped.

Q: Does the use of Propofol Lipuro affect driving after the procedure?

A: Yes, official patient information strictly advises that patients must not drive or operate machinery for a certain period following the administration of Propofol. The clinical team provides guidance on when it is safe to resume these activities.

Q: What is the guidance on fasting before a procedure involving Propofol Lipuro?

A: Propofol can lead to the loss of protective airway reflexes, which raises the risk of aspiration. Therefore, clinical guidelines recommend that the drug should only be administered to patients who have adhered to appropriate fasting (NPO) requirements, which the clinical team typically provides.

Q: Do official sources address concerns about dependency or abuse potential?

A: Official regulatory bodies, such as the US DEA, have addressed the drug’s potential for abuse and dependence. This is the primary reason Propofol's administration is legally restricted to be conducted only by or under the direct supervision of an anesthesiologist or licensed physician.

Q: Are there any known interactions with common vitamins or minerals?

A: The official drug information notes that there may be an increased loss of the mineral zinc in the urine. For certain patients on prolonged Propofol therapy, supplemental zinc may be considered by healthcare providers.

Q: How is the post-procedure recovery period generally described for Propofol Lipuro?

A: Studies and official sources often describe the recovery period as smooth and rapid. Propofol is often associated with a minimal occurrence of common post-operative issues like nausea and vomiting.

Storage and Disposal of Propofol Lipuro

The storage and disposal of Propofol Lipuro are governed by specific regulatory requirements to maintain the stability of its oil-in-water emulsion formulation and prevent contamination.

---

Official Storage Conditions

Requirement	Rule based on Regulatory Documents
Temperature	Must be stored below 25°C and must not be frozen.
Light Protection	Keep vials or ampoules in the outer carton to protect the contents from light.
Child Safety	Keep the medicine out of the sight and reach of children.

Stability and Handling

Due to the absence of antimicrobial preservatives, strict aseptic technique must always be maintained during handling. The product is intended for single use in one patient, and administration must commence without delay after opening. The contents must be visually inspected, and the vial must be shaken before use; if two layers are visible, the emulsion must not be used.

Disposal Requirements

Any unused portion of the ampoule or vial must be discarded immediately after use. All remaining medicinal product and waste materials derived from it should be disposed of in accordance with local requirements.